kabutan

Shionogi & Co.,Ltd.(4507) Summary

4507
TSE Prime
Shionogi & Co.,Ltd.
3,117.0
JPY
+39.0
(+1.27%)
Jan 29, 1:39 pm JST
20.36
USD
Jan 28, 11:39 pm EST
Result
PTS
outside of trading hours
3,114.9
Jan 29, 1:37 pm JST
Summary Chart Historical News Financial Result
PER
14.1
PBR
1.85
Yield
2.12%
Margin Trading Ratio
14.47
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
3,022.0 JPY 19.73 USD
Previous Close Jan 28
3,078.0 JPY 20.16 USD
High Jan 29, 12:36 pm
3,121.0 JPY 20.39 USD
Low Jan 29, 9:06 am
3,021.0 JPY 19.73 USD
Volume
1,601,100
Trading Value
4.90B JPY 0.03B USD
VWAP
3060.36 JPY 20.0 USD
Minimum Trading Value
311,700 JPY 2,036 USD
Market Cap
2.77T JPY 0.02T USD
Number of Trades
4,532
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
High
1-Year Average
4,509
1-Year High Apr 7, 2025
13,762
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 279,600 1,156,800 4.14
Jan 16, 2026 242,100 1,136,400 4.69
Jan 9, 2026 252,400 1,054,400 4.18
Dec 26, 2025 241,200 1,030,800 4.27
Dec 19, 2025 202,500 805,500 3.98
Company Profile
Shionogi & Co., Ltd. has seen significant growth in its anti-HIV drugs. The company has strengths in hyperlipidemia medications, pain management, and the infection field. It is also accelerating its expansion into overseas markets.
Sector
Pharmaceuticals
Shionogi & Co., Ltd. engages in the research and development, procurement, manufacturing, and sales of prescription pharmaceuticals, with a particular strength in the field of infectious diseases. The company has numerous subsidiaries and affiliated companies both domestically and internationally, enabling a global business operation. Key subsidiaries include Shionogi Pharma, which handles manufacturing and contract manufacturing; Shionogi Healthcare, which develops OTC pharmaceutical business; and Shionogi TechnoAdvance Research, which provides research support for drug discovery. Overseas, Shionogi has established bases primarily in the United States, as well as in Europe and Asia, to promote local research and development and sales activities. In China, in particular, the company operates through multiple subsidiaries, demonstrating its active pursuit of expansion into foreign markets.